{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:57Z","timestamp":1793134137727,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hubei Province Medical Youth Top Talent Project","award":["EWT [2023] 65, Oncology"],"award-info":[{"award-number":["EWT [2023] 65, Oncology"]}]},{"name":"Hubei Province Medical Youth Top Talent Project","award":["EWT [2023] 65, Oncology"],"award-info":[{"award-number":["EWT [2023] 65, Oncology"]}]},{"name":"Hubei Province Medical Youth Top Talent Project","award":["EWT [2023] 65, Oncology"],"award-info":[{"award-number":["EWT [2023] 65, Oncology"]}]},{"name":"Hubei Province Medical Youth Top Talent Project","award":["EWT [2023] 65, Oncology"],"award-info":[{"award-number":["EWT [2023] 65, Oncology"]}]},{"name":"Hubei Province Medical Youth Top Talent Project","award":["EWT [2023] 65, Oncology"],"award-info":[{"award-number":["EWT [2023] 65, Oncology"]}]},{"name":"Hubei Province Medical Youth Top Talent Project","award":["EWT [2023] 65, Oncology"],"award-info":[{"award-number":["EWT [2023] 65, Oncology"]}]},{"name":"Hubei Cancer Hospital Biomedical Center Research Project","award":["2022SWZX03"],"award-info":[{"award-number":["2022SWZX03"]}]},{"name":"Hubei Cancer Hospital Biomedical Center Research Project","award":["2022SWZX03"],"award-info":[{"award-number":["2022SWZX03"]}]},{"name":"Hubei Cancer Hospital Biomedical Center Research Project","award":["2022SWZX03"],"award-info":[{"award-number":["2022SWZX03"]}]},{"name":"Hubei Cancer Hospital Biomedical Center Research Project","award":["2022SWZX03"],"award-info":[{"award-number":["2022SWZX03"]}]},{"name":"Hubei Cancer Hospital Biomedical Center Research Project","award":["2022SWZX03"],"award-info":[{"award-number":["2022SWZX03"]}]},{"name":"Hubei Cancer Hospital Biomedical Center Research Project","award":["2022SWZX03"],"award-info":[{"award-number":["2022SWZX03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03288-3","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:34:40Z","timestamp":1753742080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights"],"prefix":"10.1007","volume":"16","author":[{"given":"Lingzi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7185-6787","authenticated-orcid":false,"given":"Xinhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"3288_CR1","volume-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians; 2024."},{"key":"3288_CR2","doi-asserted-by":"crossref","unstructured":"Kim M, Chung YR, Kim HJ, Woo JW, Ahn S, Park SY. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020;22(1):32.","DOI":"10.1186\/s13058-020-01267-w"},{"issue":"1","key":"3288_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/his.14804","volume":"82","author":"RI Udayasiri","year":"2022","unstructured":"Udayasiri RI, Luo T, Gorringe KL, Fox SB. Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast. Histopathology. 2022;82(1):106\u201318.","journal-title":"Histopathology"},{"issue":"1","key":"3288_CR4","first-page":"7","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"3288_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3322\/caac.21412","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, Racial disparity in mortality by state. Cancer J Clin. 2017;67(6):439\u201348.","journal-title":"Cancer J Clin"},{"issue":"8","key":"3288_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jjco\/hyx059","volume":"47","author":"C Kanbayashi","year":"2017","unstructured":"Kanbayashi C, Iwata H. Current approach and future perspective for ductal carcinoma in situ of the breast. Jpn J Clin Oncol. 2017;47(8):671\u20137.","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"3288_CR7","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1016\/S1470-2045(16)30367-9","volume":"17","author":"JR Benson","year":"2016","unstructured":"Benson JR, Jatoi I, Toi M. Treatment of low-risk ductal carcinoma in situ: is nothing better than something? Lancet Oncol. 2016;17(10):e442\u201351.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3288_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","volume":"121","author":"M van Seijen","year":"2019","unstructured":"van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, Verschuur E, Lane J, Jonkers J, Rea DW, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019;121(4):285\u201392.","journal-title":"Br J Cancer"},{"issue":"10445","key":"3288_CR9","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/S0140-6736(24)00425-2","volume":"403","author":"S Delaloge","year":"2024","unstructured":"Delaloge S, Khan SA, Wesseling J, Whelan T. Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment. Lancet. 2024;403(10445):2734\u201346.","journal-title":"Lancet"},{"issue":"8","key":"3288_CR10","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","volume":"31","author":"MS Toss","year":"2018","unstructured":"Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC, Aneja R, Green AR, Ellis IO, Rakha EA. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Mod Pathol. 2018;31(8):1226\u201336.","journal-title":"Mod Pathol"},{"issue":"5","key":"3288_CR11","doi-asserted-by":"publisher","first-page":"150923","DOI":"10.1016\/j.soncn.2019.08.002","volume":"35","author":"M Abbott","year":"2019","unstructured":"Abbott M, Ustoyev Y. Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs. 2019;35(5):150923.","journal-title":"Semin Oncol Nurs"},{"key":"3288_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.semcancer.2019.12.018","volume":"72","author":"CN Baxevanis","year":"2021","unstructured":"Baxevanis CN, Fortis SP, Perez SA. The balance between breast cancer and the immune system: challenges for prognosis and clinical benefit from immunotherapies. Semin Cancer Biol. 2021;72:76\u201389.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"3288_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105\u201313.","journal-title":"J Clin Oncol"},{"issue":"Pt 2","key":"3288_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","volume":"52","author":"MV Dieci","year":"2018","unstructured":"Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D\u2019Alfonso TM, Demaria S, Castaneda C, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the international Immuno-Oncology biomarker working group on breast cancer. Semin Cancer Biol. 2018;52(Pt 2):16\u201325.","journal-title":"Semin Cancer Biol"},{"key":"3288_CR15","doi-asserted-by":"crossref","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259\u201371.","DOI":"10.1093\/annonc\/mdu450"},{"issue":"9","key":"3288_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/jclinpath-2019-206252","volume":"73","author":"J Yeong","year":"2020","unstructured":"Yeong J, Tan T, Chow ZL, Cheng Q, Lee B, Seet A, Lim JX, Lim JCT, Ong CCH, Thike AA, et al. Multiplex immunohistochemistry\/immunofluorescence (mIHC\/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC. J Clin Pathol. 2020;73(9):557\u201362.","journal-title":"J Clin Pathol"},{"key":"3288_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.semcancer.2018.07.001","volume":"52","author":"F Klauschen","year":"2018","unstructured":"Klauschen F, M\u00fcller KR, Binder A, Bockmayr M, H\u00e4gele M, Seegerer P, Wienert S, Pruneri G, de Maria S, Badve S, et al. Scoring of tumor-infiltrating lymphocytes: from visual Estimation to machine learning. Sem Cancer Biol. 2018;52:151\u20137.","journal-title":"Sem Cancer Biol"},{"issue":"4","key":"3288_CR18","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1002\/cpz1.118","volume":"1","author":"LJ Tracey","year":"2021","unstructured":"Tracey LJ, An Y, Justice MJ. CyTOF: an emerging technology for Single-Cell proteomics in the mouse. Curr Protoc. 2021;1(4):e118.","journal-title":"Curr Protoc"},{"issue":"9","key":"3288_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","volume":"33","author":"C Denkert","year":"2015","unstructured":"Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983\u201391.","journal-title":"J Clin Oncol"},{"issue":"27","key":"3288_CR20","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959\u201366.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3288_CR21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02\u201398. J Clin Oncol. 2013;31(7):860\u20137.","journal-title":"J Clin Oncol"},{"key":"3288_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59.","journal-title":"J Immunother Cancer"},{"key":"3288_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.breast.2017.07.005","volume":"35","author":"C Solinas","year":"2017","unstructured":"Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: current state of the Art. Breast. 2017;35:142\u201350.","journal-title":"Breast"},{"issue":"1","key":"3288_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3288_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/annonc\/mdw623","volume":"28","author":"G Pruneri","year":"2017","unstructured":"Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S, et al. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2017;28(2):321\u20138.","journal-title":"Ann Oncol"},{"issue":"6","key":"3288_CR26","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/his.14055","volume":"76","author":"AA Thike","year":"2020","unstructured":"Thike AA, Chen X, Koh VCY, Binte Md Nasir ND, Yeong JPS, Bay BH, Tan PH. Higher densities of tumour-infiltrating lymphocytes and CD4\u2009+\u2009T cells predict recurrence and progression of ductal carcinoma in situ of the breast. Histopathology. 2020;76(6):852\u201364.","journal-title":"Histopathology"},{"issue":"8","key":"3288_CR27","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544\u201350.","journal-title":"Ann Oncol"},{"issue":"17","key":"3288_CR28","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1158\/1078-0432.CCR-17-0743","volume":"23","author":"S Hendry","year":"2017","unstructured":"Hendry S, Pang J-MB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, Mann GB, Gorringe KL, Fox SB. Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features. Clin Cancer Res. 2017;23(17):5210\u20137.","journal-title":"Clin Cancer Res"},{"key":"3288_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2022.01.016","volume":"168","author":"A Schiza","year":"2022","unstructured":"Schiza A, Thurfjell V, Stenmark Tullberg A, Olofsson H, Lindberg A, Holmberg E, Bremer T, Micke P, Karlsson P, W\u00e4rnberg F, et al. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. Eur J Cancer. 2022;168:128\u201337.","journal-title":"Eur J Cancer"},{"issue":"7","key":"3288_CR30","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/cam4.715","volume":"5","author":"M Morita","year":"2016","unstructured":"Morita M, Yamaguchi R, Tanaka M, Tse GM, Yamaguchi M, Kanomata N, Naito Y, Akiba J, Hattori S, Minami S, et al. CD8\u2009+\u2009tumor-infiltrating lymphocytes contribute to spontaneous healing in HER2\u2010positive ductal carcinoma in situ. Cancer Med. 2016;5(7):1607\u201318.","journal-title":"Cancer Med"},{"issue":"1","key":"3288_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10549-022-06553-z","volume":"193","author":"H Jia","year":"2022","unstructured":"Jia H, Zhao P, Chen Z, Wang G, Dong X, Xing X, Tan X, Wang C. Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast. Breast Cancer Res Treat. 2022;193(1):111\u201320.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"3288_CR32","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1073\/pnas.1104303108","volume":"109","author":"B Ruffell","year":"2012","unstructured":"Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012;109(8):2796\u2013801.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3288_CR33","doi-asserted-by":"publisher","first-page":"101042831769502","DOI":"10.1177\/1010428317695023","volume":"39","author":"A Ravelli","year":"2017","unstructured":"Ravelli A, Roviello G, Cretella D, Cavazzoni A, Biondi A, Cappelletti MR, Zanotti L, Ferrero G, Ungari M, Zanconati F, et al. Tumor-infiltrating lymphocytes and breast cancer: beyond the prognostic and predictive utility. Tumour Biol. 2017;39(4):1010428317695023.","journal-title":"Tumour Biol"},{"issue":"3","key":"3288_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/modpathol.2015.158","volume":"29","author":"E Thompson","year":"2016","unstructured":"Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016;29(3):249\u201358.","journal-title":"Mod Pathol"},{"key":"3288_CR35","doi-asserted-by":"crossref","unstructured":"Beguinot M, Dauplat M-M, Kwiatkowski F, Lebouedec G, Tixier L, Pomel C, Penault-Llorca F, Radosevic-Robin N. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cancer. 2018;18(1):129.","DOI":"10.1186\/s12885-018-4013-6"},{"issue":"10","key":"3288_CR36","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/s41416-020-0797-7","volume":"122","author":"MS Toss","year":"2020","unstructured":"Toss MS, Abidi A, Lesche D, Joseph C, Mahale S, Saunders H, Kader T, Miligy IM, Green AR, Gorringe KL, et al. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. Br J Cancer. 2020;122(10):1496\u2013506.","journal-title":"Br J Cancer"},{"issue":"10","key":"3288_CR37","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1245\/s10434-019-07562-x","volume":"26","author":"F Darvishian","year":"2019","unstructured":"Darvishian F, Ozerdem U, Adams S, Chun J, Pirraglia E, Kaplowitz E, Guth A, Axelrod D, Shapiro R, Price A, et al. Tumor-Infiltrating lymphocytes in a contemporary cohort of women with ductal carcinoma in situ (DCIS). Ann Surg Oncol. 2019;26(10):3337\u201343.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3288_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","volume":"161","author":"MJ Campbell","year":"2016","unstructured":"Campbell MJ, Baehner F, O\u2019Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, et al. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2016;161(1):17\u201328.","journal-title":"Breast Cancer Res Treat"},{"key":"3288_CR39","doi-asserted-by":"crossref","unstructured":"Genco IS, Ozgultekin B, Hosseini H, Hackman K, Ferreira L, Santagada E, Wahl S, Hajiyeva S. High EZH2 expression in ductal carcinoma in situ diagnosed on breast core needle biopsy is an independent predictive factor for upgrade on surgical excision. Pathol Res Pract. 2020;216(12):153283.","DOI":"10.1016\/j.prp.2020.153283"},{"issue":"7","key":"3288_CR40","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41416-022-01888-2","volume":"127","author":"MM Almekinders","year":"2022","unstructured":"Almekinders MM, Bismeijer T, Kumar T, Yang F, Thijssen B, van der Linden R, van Rooijen C, Vonk S, Sun B, Parra Cuentas ER, et al. Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk. Br J Cancer. 2022;127(7):1201\u201313.","journal-title":"Br J Cancer"},{"issue":"2","key":"3288_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/ajcp\/aqz020","volume":"152","author":"JM Ubago","year":"2019","unstructured":"Ubago JM, Blanco LZ Jr, Shen T, Siziopikou KP. The PD-1\/PD-L1 axis in HER2\u2009+\u2009Ductal carcinoma in situ (DCIS) of the breast. Am J Clin Pathol. 2019;152(2):169\u201376.","journal-title":"Am J Clin Pathol"},{"key":"3288_CR42","doi-asserted-by":"crossref","unstructured":"Xu F-F, Zheng S-F, Xu C, Cai G, Wang S-B, Qi W-X, Wang C-F, Chen J-Y, Lu C. Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ. Oncoimmunology. 2021;10(1):1875637.","DOI":"10.1080\/2162402X.2021.1875637"},{"issue":"2","key":"3288_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41379-019-0331-8","volume":"33","author":"MC Agahozo","year":"2020","unstructured":"Agahozo MC, van Bockstal MR, Groenendijk FH, van den Bosch TPP, Westenend PJ, van Deurzen CHM. Ductal carcinoma in situ of the breast: immune cell composition according to subtype. Mod Pathol. 2020;33(2):196\u2013205.","journal-title":"Mod Pathol"},{"issue":"2","key":"3288_CR44","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/his.13217","volume":"71","author":"I Miligy","year":"2017","unstructured":"Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, Mukherjee A, Chapman C, Ellis IO, Green AR, et al. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology. 2017;71(2):258\u201368.","journal-title":"Histopathology"},{"issue":"6","key":"3288_CR45","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00428-019-02735-1","volume":"476","author":"X-Y Chen","year":"2020","unstructured":"Chen X-Y, Thike AA, Md Nasir ND, Koh VCY, Bay BH, Tan PH. Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence. Virchows Arch. 2020;476(6):825\u201333.","journal-title":"Virchows Arch"},{"issue":"2","key":"3288_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/jclinpath-2011-200355","volume":"65","author":"SMA Mahmoud","year":"2012","unstructured":"Mahmoud SMA, Lee AHS, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 2012;65(2):159\u201363.","journal-title":"J Clin Pathol"},{"issue":"5","key":"3288_CR47","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.3892\/ijo.2016.3680","volume":"49","author":"J Ding","year":"2016","unstructured":"Ding J, Guo C, Hu P, Chen J, Liu Q, Wu X, Cao Y, Wu J. CSF1 is involved in breast cancer progression through inducing monocyte differentiation and homing. Int J Oncol. 2016;49(5):2064\u201374.","journal-title":"Int J Oncol"},{"key":"3288_CR48","doi-asserted-by":"crossref","unstructured":"Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, M\u00f6nkk\u00f6nen J, Kellokumpu-Lehtinen P-L, Lauttia S, Tynninen O, Joensuu H et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 2015;17(1):101.","DOI":"10.1186\/s13058-015-0621-0"},{"issue":"2","key":"3288_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/tbj.12368","volume":"21","author":"MJ Silverstein","year":"2015","unstructured":"Silverstein MJ, Lagios MD. Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the university of Southern california\/van Nuys (USC\/VNPI) prognostic index. Breast J. 2015;21(2):127\u201332.","journal-title":"Breast J"},{"key":"3288_CR50","doi-asserted-by":"crossref","unstructured":"Niwi\u0144ska A, Olszewski WP. The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer. Breast Cancer Res. 2021;23(1):118.","DOI":"10.1186\/s13058-021-01494-9"},{"issue":"34","key":"3288_CR51","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","volume":"24","author":"GJ Bates","year":"2006","unstructured":"Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of High-Risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373\u201380.","journal-title":"J Clin Oncol"},{"key":"3288_CR52","doi-asserted-by":"crossref","unstructured":"Farolfi A, Petracci E, Serra L, Ravaioli A, Bravaccini S, Ravaioli S, Tumedei MM, Ulivi P, Canale M, Puccetti M et al. Tumor-Infiltrating lymphocytes (TILs) and risk of a second breast event after a ductal carcinoma in situ. Front Oncol. 2020;10:1486.","DOI":"10.3389\/fonc.2020.01486"},{"issue":"9","key":"3288_CR53","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/modpathol.2015.79","volume":"28","author":"A Knopfelmacher","year":"2015","unstructured":"Knopfelmacher A, Fox J, Lo Y, Shapiro N, Fineberg S. Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. Mod Pathol. 2015;28(9):1167\u201373.","journal-title":"Mod Pathol"},{"issue":"5","key":"3288_CR54","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/his.14181","volume":"77","author":"M Komforti","year":"2020","unstructured":"Komforti M, Badve SS, Harmon B, Lo Y, Fineberg S. Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)\u2014assessment with three different methodologies and correlation with oncotype DX DCIS score. Histopathology. 2020;77(5):749\u201359.","journal-title":"Histopathology"},{"issue":"9","key":"3288_CR55","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/modpathol.2015.75","volume":"28","author":"KL Gorringe","year":"2015","unstructured":"Gorringe KL, Hunter SM, Pang J-M, Opeskin K, Hill P, Rowley SM, Choong DYH, Thompson ER, Dobrovic A, Fox SB, et al. Copy number analysis of ductal carcinoma in situ with and without recurrence. Mod Pathol. 2015;28(9):1174\u201384.","journal-title":"Mod Pathol"},{"issue":"4","key":"3288_CR56","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10911-018-9409-z","volume":"23","author":"AC Nelson","year":"2018","unstructured":"Nelson AC, Machado HL, Schwertfeger KL. Breaking through to the other side: microenvironment contributions to DCIS initiation and progression. J Mammary Gland Biol Neoplasia. 2018;23(4):207\u201321.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"6024","key":"3288_CR57","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Sci (New York NY). 2011;331(6024):1565\u201370.","journal-title":"Sci (New York NY)"},{"issue":"1","key":"3288_CR58","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12967-024-05134-6","volume":"22","author":"Y Chen","year":"2024","unstructured":"Chen Y, Yu D, Qian H, Shi Y, Tao Z. CD8(+) T cell-based cancer immunotherapy. J Translational Med. 2024;22(1):394.","journal-title":"J Translational Med"},{"issue":"10","key":"3288_CR59","doi-asserted-by":"publisher","first-page":"e1218106","DOI":"10.1080\/2162402X.2016.1218106","volume":"5","author":"M Semeraro","year":"2016","unstructured":"Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, Sauvat A, Senovilla L, Vacchelli E, Bloy N, et al. The ratio of CD8(+)\/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Oncoimmunology. 2016;5(10):e1218106.","journal-title":"Oncoimmunology"},{"issue":"9","key":"3288_CR60","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1136\/jcp.2005.031252","volume":"59","author":"MR Hussein","year":"2006","unstructured":"Hussein MR. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol. 2006;59(9):972\u20137.","journal-title":"J Clin Pathol"},{"issue":"10","key":"3288_CR61","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","volume":"45","author":"G Ciriello","year":"2013","unstructured":"Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127\u201333.","journal-title":"Nat Genet"},{"issue":"1","key":"3288_CR62","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/his.12796","volume":"68","author":"JM Pang","year":"2016","unstructured":"Pang JM, Gorringe KL, Fox SB. Ductal carcinoma in situ - update on risk assessment and management. Histopathology. 2016;68(1):96\u2013109.","journal-title":"Histopathology"},{"key":"3288_CR63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10.","journal-title":"Biomark Res"},{"issue":"1","key":"3288_CR64","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13058-017-0817-6","volume":"19","author":"F Beca","year":"2017","unstructured":"Beca F, Kensler K, Glass B, Schnitt SJ, Tamimi RM, Beck AH. EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the nurses\u2019 health studies. Breast Cancer Research: BCR. 2017;19(1):21.","journal-title":"Breast Cancer Research: BCR"},{"issue":"10","key":"3288_CR65","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","volume":"7","author":"CR Del Gil","year":"2017","unstructured":"Del Gil CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 2017;7(10):1098\u2013115.","journal-title":"Cancer Discov"},{"issue":"2","key":"3288_CR66","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10549-013-2556-4","volume":"139","author":"A Lal","year":"2013","unstructured":"Lal A, Chan L, DeVries S, Chin K, Scott GK, Benz CC, Chen Y-Y, Waldman FM, Hwang ES. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat. 2013;139(2):381\u201390.","journal-title":"Breast Cancer Res Treat"},{"issue":"25","key":"3288_CR67","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","volume":"184","author":"C Cui","year":"2021","unstructured":"Cui C, Wang J, Fagerberg E, Chen PM, Connolly KA, Damo M, Cheung JF, Mao T, Askari AS, Chen S, et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell. 2021;184(25):6101\u2013e61186113.","journal-title":"Cell"},{"issue":"7","key":"3288_CR68","doi-asserted-by":"publisher","first-page":"e0199034","DOI":"10.1371\/journal.pone.0199034","volume":"13","author":"RAM Rossetti","year":"2018","unstructured":"Rossetti RAM, Lorenzi NPC, Yokochi K, Rosa M, Benevides L, Margarido PFR, Baracat EC, Carvalho JP, Villa LL, Lepique AP. B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. PLoS ONE. 2018;13(7):e0199034.","journal-title":"PLoS ONE"},{"issue":"4","key":"3288_CR69","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.immuni.2018.08.012","volume":"49","author":"S Hong","year":"2018","unstructured":"Hong S, Zhang Z, Liu H, Tian M, Zhu X, Zhang Z, Wang W, Zhou X, Zhang F, Ge Q, et al. B cells are the dominant antigen-Presenting cells that activate Naive CD4(+) T cells upon immunization with a Virus-Derived nanoparticle antigen. Immunity. 2018;49(4):695\u2013e708694.","journal-title":"Immunity"},{"key":"3288_CR70","doi-asserted-by":"publisher","first-page":"582657","DOI":"10.3389\/fimmu.2020.582657","volume":"11","author":"J Shang","year":"2020","unstructured":"Shang J, Zha H, Sun Y. Phenotypes, functions, and clinical relevance of regulatory B cells in cancer. Front Immunol. 2020;11:582657.","journal-title":"Front Immunol"},{"issue":"7885","key":"3288_CR71","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-021-04082-1","volume":"599","author":"B Zhang","year":"2021","unstructured":"Zhang B, Vogelzang A, Miyajima M, Sugiura Y, Wu Y, Chamoto K, Nakano R, Hatae R, Menzies RJ, Sonomura K, et al. B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity. Nature. 2021;599(7885):471\u20136.","journal-title":"Nature"},{"issue":"3","key":"3288_CR72","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2017","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2017;18(3):153\u201367.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3288_CR73","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"34","author":"SH Baumeister","year":"2016","unstructured":"Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34(1):539\u201373.","journal-title":"Annu Rev Immunol"},{"issue":"230","key":"3288_CR74","doi-asserted-by":"publisher","first-page":"ra46","DOI":"10.1126\/scisignal.2002796","volume":"5","author":"N Patsoukis","year":"2012","unstructured":"Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012;5(230):ra46.","journal-title":"Sci Signal"},{"issue":"10","key":"3288_CR75","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jclinpath-2016-203990","volume":"70","author":"A Pol\u00f3nia","year":"2017","unstructured":"Pol\u00f3nia A, Pinto R, Cameselle-Teijeiro JF, Schmitt FC, Paredes J. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. J Clin Pathol. 2017;70(10):860\u20137.","journal-title":"J Clin Pathol"},{"issue":"1","key":"3288_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","volume":"9","author":"V Debien","year":"2023","unstructured":"Debien V, De Caluw\u00e9 A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1):7.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"3288_CR77","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","volume":"5","author":"LA Emens","year":"2019","unstructured":"Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, et al. Long-term clinical outcomes and biomarker analyses of Atezolizumab therapy for patients with metastatic Triple-Negative breast cancer: A phase 1 study. JAMA Oncol. 2019;5(1):74\u201382.","journal-title":"JAMA Oncol"},{"issue":"3","key":"3288_CR78","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405\u201311.","journal-title":"Ann Oncol"},{"issue":"22","key":"3288_CR79","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im SA, Shaw Wright G, et al. Atezolizumab and Nab-Paclitaxel in advanced Triple-Negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321.","journal-title":"N Engl J Med"},{"issue":"10265","key":"3288_CR80","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328.","journal-title":"Lancet"},{"issue":"8","key":"3288_CR81","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","volume":"27","author":"JM Kim","year":"2016","unstructured":"Kim JM, Chen DS. Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492\u2013504.","journal-title":"Ann Oncol"},{"issue":"8","key":"3288_CR82","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"LA Emens","year":"2021","unstructured":"Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Di\u00e9ras V, Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A, et al. Atezolizumab and nab-Paclitaxel in advanced Triple-Negative breast cancer: biomarker evaluation of the IMpassion130 study. JNCI J Natl Cancer Inst. 2021;113(8):1005\u201316.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"2","key":"3288_CR83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/path.1700380202","volume":"38","author":"R Muir","year":"1934","unstructured":"Muir R, Aitkenhead AC. The healing of intra-duct carcinoma of the mamma. J Pathol Bacteriol. 1934;38(2):117\u201327.","journal-title":"J Pathol Bacteriol"},{"issue":"12","key":"3288_CR84","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1002\/cam4.952","volume":"5","author":"Y Horimoto","year":"2016","unstructured":"Horimoto Y, Hayashi T, Arakawa A. Pathology of healing: what else might we look at? Cancer Med. 2016;5(12):3586\u20137.","journal-title":"Cancer Med"},{"issue":"2","key":"3288_CR85","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2325\/jbcs.12.140","volume":"12","author":"R Horii","year":"2005","unstructured":"Horii R, Akiyama F, Kasumi F, Koike M, Sakamoto G. Spontaneous healing of breast cancer. Breast Cancer (Tokyo Japan). 2005;12(2):140\u20134.","journal-title":"Breast Cancer (Tokyo Japan)"},{"issue":"6","key":"3288_CR86","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/PAI.0b013e3181a1743a","volume":"17","author":"M Chivukula","year":"2009","unstructured":"Chivukula M, Domfeh A, Carter G, Tseng G, Dabbs DJ. Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications. Appl Immunohistochem Mol Morphol. 2009;17(6):495\u20139.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"3288_CR87","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/1097-0142(19830201)51:3<553::AID-CNCR2820510332>3.0.CO;2-T","volume":"51","author":"H Trau","year":"1983","unstructured":"Trau H, Rigel DS, Harris MN, Kopf AW, Friedman RJ, Gumport SL, Bart RS, Grier WR. Metastases of thin melanomas. Cancer. 1983;51(3):553\u20136.","journal-title":"Cancer"},{"issue":"9","key":"3288_CR88","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1001\/archderm.1985.01660090041010","volume":"121","author":"PH Cooper","year":"1985","unstructured":"Cooper PH, Wanebo HJ, Hagar RW. Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. Arch Dermatol. 1985;121(9):1127\u201331.","journal-title":"Arch Dermatol"},{"issue":"2","key":"3288_CR89","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2559.2007.02909.x","volume":"52","author":"J Bezic","year":"2007","unstructured":"Bezic J. DCIS with foreign body giant cells as a sign of \u2018healing\u2019 phenomenon\u2014a case report. Histopathology. 2007;52(2):240\u20131.","journal-title":"Histopathology"},{"key":"3288_CR90","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C, Depil S. Cold tumors: A therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168.","journal-title":"Front Immunol"},{"issue":"6","key":"3288_CR91","doi-asserted-by":"publisher","first-page":"100636","DOI":"10.1016\/j.esmoop.2022.100636","volume":"7","author":"A Giannoudis","year":"2022","unstructured":"Giannoudis A, Vare\u0161lija D, Sharma V, Zakaria R, Platt-Higgins A, Rudland PS, Jenkinson MD, Young LS, Palmieri C. Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. ESMO Open. 2022;7(6):100636.","journal-title":"ESMO Open"},{"issue":"1","key":"3288_CR92","doi-asserted-by":"publisher","first-page":"e1523097","DOI":"10.1080\/2162402X.2018.1523097","volume":"8","author":"J Krombach","year":"2019","unstructured":"Krombach J, Hennel R, Brix N, Orth M, Schoetz U, Ernst A, Schuster J, Zuchtriegel G, Reichel CA, Bierschenk S, et al. Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived damps trigger endothelial cell activation and recruitment of myeloid cells. Oncoimmunology. 2019;8(1):e1523097.","journal-title":"Oncoimmunology"},{"issue":"2","key":"3288_CR93","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124(2):687\u201395.","journal-title":"J Clin Investig"},{"key":"3288_CR94","doi-asserted-by":"publisher","first-page":"110873","DOI":"10.1016\/j.biopha.2020.110873","volume":"132","author":"B Lin","year":"2020","unstructured":"Lin B, Du L, Li H, Zhu X, Cui L, Li X. Tumor-infiltrating lymphocytes: warriors fight against tumors powerfully. Biomed Pharmacother. 2020;132:110873.","journal-title":"Biomed Pharmacother"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03288-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03288-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03288-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:04:11Z","timestamp":1757315051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03288-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3288"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03288-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1435"}}